文献速递淋巴瘤

伴11q异常高级别B细胞淋巴瘤51例临床病理与疗效分析

[A retrospective analysis of clinicopathological features and efficacy in 51 patients with high-grade B-cell lymphoma with 11q abnormalities].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

本研究回顾性分析河南省肿瘤医院51例伴11号染色体长臂异常的高级别B细胞淋巴瘤(HGBCL-11q)患者资料,总结其临床病理及分子遗传学特征,并比较不同强度化疗方案的疗效与生存差异。结果显示该病具有特征性表现,含利妥昔单抗的高强度化疗可显著提高完全缓解率并延长无进展生存期。

要点

  • HGBCL-11q多见于消化系统,呈生发中心B细胞免疫表型,Ki-67多≥90%。
  • 荧光原位杂交证实无MYC基因重排,常见DDX3X、PCLO、TP53、GNA13突变。
  • 含利妥昔单抗的高强度化疗完全缓解率与无进展生存期均优于非高强度组。

核心结论

  • HGBCL-11q具有特征性临床病理表现及分子遗传学特征,含利妥昔单抗的高强度化疗可显著提高缓解率并改善生存。

研究设计与样本

  • 回顾性分析河南省肿瘤医院51例HGBCL-11q患者资料,比较不同治疗强度组间疗效与生存差异。

主要发现

  • 51例患者中位年龄52(5~84)岁,男女比例1.22∶1,消化系统为最常见发病部位(18/51,35.3%)。
  • 47例(92.2%)肿瘤细胞不同程度表达c-Myc(阳性细胞占比20%~85%),41例(80.4%)不表达Bcl-2,47例(92.2%)Ki-67增殖指数≥90%。
  • 高频突变基因包括DDX3X(60.0%,12/20)、PCLO(50.0%,10/20)、TP53(45.0%,9/20)、GNA13(40.0%,8/20)。

关键数值与推荐

  • 含利妥昔单抗的高强度治疗组完全缓解率为87.5%(21/24),非高强度组为60.9%(14/23),P=0.036。
  • 高强度组无进展生存期为(62.7±3.9)个月,非高强度组为(41.7±6.5)个月,P=0.014。

临床怎么用

  • 对HGBCL-11q患者可考虑含利妥昔单抗的高强度化疗以改善缓解率与无进展生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To investigate the clinicopathological features, molecular genetic characteristics, and efficacy of chemotherapy regimens with different intensities in high-grade B-cell lymphoma with aberrations in the long arm of chromosome 11 (HGBCL-11q), this study retrospectively analyzed the data of 51 patients with HGBCL-11q at Henan Cancer Hospital, summarized their clinical, pathological and molecular profiles, and compared the differences in therapeutic efficacy and survival outcomes between groups with different treatment intensities. The median age of the 51 patients was 52 (5 - 84) years, with a male-to-female ratio of 1.22:1, and the digestive system was the most common site of involvement (18/51, 35.3% ). The tumor cells exhibited a germinal center B-cell immunophenotype: 47 patients (92.2% ) showed variable c-Myc expression in tumor cells (the proportion of positive cells ranged from 20% to 85% ), 41 patients (80.4% ) were negative for Bcl-2 expression, and 47 patients (92.2% ) had a Ki-67 proliferation index ≥90%. Fluorescence in situ hybridization confirmed the absence of MYC gene rearrangement and the presence of characteristic aberrations in 11q; recurrently mutated genes included DDX3X (60.0%, 12/20), PCLO (50.0%, 10/20), TP53 (45.0%, 9/20) and GNA13 (40.0%, 8/20), et al. The complete response rate in the rituximab-containing high-intensity chemotherapy group was significantly higher than that in the non-high-intensity group [87.5% (21/24) vs 60.9% (14/23), P=0.036], with longer progression-free survival [ (62.7±3.9) months vs (41.7±6.5) months, P=0.014]. In conclusion, HGBCL-11q has distinctive clinicopathological manifestations and molecular genetic features, and rituximab-containing high-intensity chemotherapy can significantly improve the response rate and survival of patients. 为探讨伴11号染色体长臂(11q)异常的高级别B细胞淋巴瘤(HGBCL-11q)的临床病理特征、分子遗传学特点及不同强度化疗方案的疗效,本研究回顾性分析就诊于河南省肿瘤医院的51例HGBCL-11q患者资料,总结其临床及病理分子特征,比较不同治疗强度组间的疗效与生存差异。结果显示,51例患者中位年龄52(5~84)岁,男女比例为1.22∶1,消化系统为最常见发病部位(18/51,35.3%)。肿瘤细胞呈生发中心B细胞免疫表型,47例(92.2%)肿瘤细胞不同程度表达c-Myc(阳性细胞占比20%~85%),41例(80.4%)不表达Bcl-2,47例(92.2%)Ki-67增殖指数≥90%。荧光原位杂交检测提示无MYC基因重排,特征性出现11q异常,高频突变基因包括DDX3X(60.0%,12/20)、PCLO(50.0%,10/20)、TP53(45.0%,9/20)、GNA13(40.0%,8/20)等。含利妥昔单抗的高强度治疗组完全缓解率显著高于标准治疗组[87.5%(21/24)对60.9%(14/23),P=0.036],且无进展生存期更长[(62.7±3.9)个月对(41.7±6.5)个月,P=0.014]。HGBCL-11q具有特征性临床病理表现及分子遗传学特征,含利妥昔单抗的高强度化疗可显著提高缓解率并改善生存。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang L, Gao G, Jin YP, et al. [A retrospective analysis of clinicopathological features and efficacy in 51 patients with high-grade B-cell lymphoma with 11q abnormalities]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706163. doi:10.3760/cma.j.cn121090-20260310-00127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。